CD8+ cytotoxic lymphocyte responses against cytomegalovirus after liver transplantation: Correlation with time from transplant to receipt of tacrolimus

Journal of Infectious Diseases

Volumn 183, Issue 6, 2001, Pages 835-843

  Hassan Walker, Aycan F ^a   Vargas Cuero, Ana L ^b   Mattes, Frank M ^a   Klenerman, Paul ^b   Lechner, Franziska ^b   Burroughs, Andrew K ^a   Griffiths, Paul D ^a   Phillips, Rodney E ^b   Emery, Vincent C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CD8 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; MATRIX PROTEIN; TACROLIMUS; TETRAMER;

ARTICLE; CELL SELECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MIDDLE AGED; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TIME FACTORS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 0035869151     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319260     Document Type: Article

References (44)

1. Cytomegalovirus
2. CMV infection of transplant recipients
3. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation
4. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
5. Quantitative effects of valaciclovir on the replication of cytomegalovirus in patients with advanced human immunodeficiency virus disease: Baseline cytomegalovirus load dictates time to disease and survival
6. Cytomegalovirus (CMV) viremia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease
7. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
8. Longitudinal fluctuations between peak virus load, donor/recipient serostatus, acute GvHD and CMV disease
9. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and anti-thymocyte globulin (ATG)
10. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes
11. The dynamics of human cytomegalovirus replication in vivo
12. Application of viral load kinetics to identify patients destined to develop cytomegalovirus disease following transplantation
13. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
14. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
15. T cell therapy of human CMV and EBV infection in immunocompromised hosts
16. FK506, an immunosuppressant targeting calcineurin function
17. Immunosuppressive strategies in transplantation
18. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells
19. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
20. + virus-specific cytotoxic T lymphocytes
21. +)-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
22. + T cells during the primary immune response to Epstein-Barr virus In vivo
23. + T lymphocytes
24. Analysis of successful immune responses in persons infected with hepatitis C
25. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections
26. +) T cells
27. Tuning to the right frequency: Cytotoxic T lymphocytes and cytomegalovirus
28. Phenotypic analysis of antigen-specific T lymphocytes
29. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: A prospective multivariate time-dependent analysis
30. Surveillance for CMV infection in orthotopic liver transplant recipients
31. + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants
32. + cytotoxic T-lymphocytes in liver transplant patients
33. + T cells specific for EBV in healthy virus carriers
34. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon
35. Detection of lymphocytes productively infected with Epstein-Barr virus in non-neoplastic tonsils
36. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
37. Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue
38. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
39. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: Results of the US multicenter FK506 Kidney Transplant Study Group
40. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression
41. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience
42. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506
43. Measurement of anti-human cytomegalovirus T cell reactivity in transplant recipients and its potential clinical use: A mini-review
44. + T cells during primary cytomegalovirus infection